What Alk-Abello does

ALK-Abelló A/S is a Danish pharmaceutical company founded in 1923 and headquartered in Hørsholm, Denmark. Listed on Nasdaq Copenhagen under the ticker ALK-B (also OTC: AKBLF), the company specializes in allergy immunotherapy and related diagnostics, employing approximately 2,900 people across offices and manufacturing sites in 20 countries. Its franchise spans two core technology platforms: subcutaneous (SCIT) and sublingual (SLIT) immunotherapy tablets for respiratory allergies (house dust mite, pollen, ragweed), and a needle-free epinephrine nasal spray (Neffy in North America, EURneffy in Europe/UK) for emergency anaphylaxis treatment. The pipeline extends into food allergies, with a peanut allergy tablet that completed a successful Phase 2 trial in April 2026.

ALK generates revenue primarily through prescription-based pharmaceutical product sales distributed via wholly-owned affiliates, specialty pharmacies, hospitals, and allergy clinics. Pricing is not publicly disclosed, but the model relies on multi-year immunotherapy regimens (creating revenue stickiness) and one-time emergency-use dispensing of nasal adrenaline. Key commercial motions include direct enterprise sales to healthcare professionals, with strong tablet momentum across Europe and China and an accelerating North America push following the January 2026 appointment of a dedicated EVP for that region. Recent regulatory wins (UK MHRA pediatric approval, Health Canada approval) and digital adherence partnerships (Smartpatient/MyTherapy) signal continued investment in geographic and therapeutic expansion under the Allergy+ 2024–2028 corporate strategy, which targets reaching 5 million patients annually by 2030.

Name

Alk-Abello

Legal name

ALK-Abelló A/S

Website

https://alk.net

Company type

Public

Founded year

1923

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ALK-Abelló A/S is a Danish pharmaceutical company developing allergy immunotherapy treatments — including sublingual tablets for respiratory allergies and the Neffy/EURneffy needle-free nasal adrenaline spray for anaphylaxis — sold via prescription through wholly-owned affiliates in 20 countries.

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

Keywords

• Allergy immunotherapy
• Respiratory allergy treatment
• Sublingual immunotherapy tablets
• Anaphylaxis emergency treatment
• Allergy diagnostics

Headquarters

HQ city

Hørsholm

HQ country

Denmark

HQ region

Europe

Offices24 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of allergy immunotherapy products including SLIT tablets, diagnostics, and treatments. Strong Q4 2025 with DKK1.73 billion in sales (3% above consensus) and DKK387 million EBIT (5% above forecast).
2. Tablet Sales: Core business driven by tablet-based allergy immunotherapy products with strong underlying momentum for tablet sales across all regions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

ALK-Abelló A/S develops, manufactures, and commercializes allergy immunotherapy products, including sublingual immunotherapy (SLIT) tablets for respiratory allergies (house dust mite, pollen, ragweed), subcutaneous immunotherapy (SCIT), the needle-free epinephrine nasal spray neffy/EURneffy for emergency treatment of anaphylaxis, and allergy diagnostics. The company sells prescription-based pharmaceutical products to healthcare professionals, pharmacies, hospitals, and allergy clinics globally across 20 countries.

Product overview

ALK-Abelló A/S is a world leader in allergy immunotherapy, offering a portfolio of sublingual immunotherapy (SLIT) tablets and needle-free treatments. The core products include neffy/EURneffy (needle-free adrenaline nasal spray for anaphylaxis), RAGWITEK/RAGWIZAX (ragweed SLIT tablets), and house dust mite and pollen SLIT tablets. The company is also developing a peanut allergy tablet which completed phase 2 trials. ALK operates across multiple disease areas including respiratory allergy, anaphylaxis, and food allergies, with production sites in Denmark, France, Spain, and the United States.

Differentiator

Problem solved

Functional benefit

Products and services

• neffy / EURneffy Needle-free adrenaline nasal spray for emergency treatment of anaphylaxis. The pocket-sized spray offers a 30-month shelf life as an alternative to traditional epinephrine autoinjectors like EpiPen. Manufactured by ALK-Abelló Pharmaceuticals Inc. Canada. Marketed as neffy in North America and EURneffy in Europe/UK.
• RAGWITEK / RAGWIZAX Sublingual immunotherapy (SLIT) tablets for treatment of allergic rhinitis caused by ragweed pollen. Marketed as RAGWITEK in the US and RAGWIZAX in other markets.
• House dust mite SLIT tablets Sublingual immunotherapy tablets for house dust mite allergy treatment.
• Pollen SLIT tablets Sublingual immunotherapy tablets for pollen allergy treatment covering various pollen allergens.
• Peanut allergy tablet Investigational sublingual immunotherapy tablet for treatment of peanut allergy. Successfully completed phase 2 trial demonstrating early onset of efficacy. Pipeline product.
• Allergy diagnostics Allergy diagnostic products used by healthcare professionals to identify and characterize allergic conditions in patients as part of the allergy treatment pathway.

Quantifiable outcome

• 95% of patients understand importance of long-term therapy
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• AravaxminorStrategic or Co-development Partner · 8 April 2026Former ALK President & CEO Carsten Hellmann and former Chief Commercial Officer Andrew Oxtoby appointed to Aravax's Board of Directors. Aravax is a clinical-stage biotechnology company developing food allergy immunotherapies. The appointment brings deep allergy therapeutics expertise to support Aravax's Phase 3 trial preparation.
• SmartpatientcoreTechnology or Integration · 4 November 2025Three-year collaboration to improve treatment adherence in allergy immunotherapy through digital patient support programs built on the MyTherapy platform. Programs have demonstrated 95% patient engagement and over 90% of patients feeling well educated about their therapy.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• DBV Technologies: Clinical-stage biotech developing Viaskin epicutaneous patches for peanut and other food allergies; competes with ALK's peanut SLIT tablet pipeline for the same food allergy patients.
• Aravax: Clinical-stage Australian biotech developing peanut allergy immunotherapy; relevant emerging competitor and partner signal (ex-ALK CEO Carsten Hellmann now on Aravax board).
• Regeneron Pharmaceuticals: Co-developer of Dupixent (with Sanofi) for asthma, CRSwNP and other type-2 allergic diseases; competes in the high-severity end of the allergic respiratory market ALK also targets.

Broad incumbents

• GlaxoSmithKline: Large respiratory franchise (e.g., Flovent, Nucala) with overlapping allergist prescriber relationships and OTC allergy products (e.g., Flonase) competing across the allergy care continuum.
• Sanofi: Global pharma with significant allergy/respiratory franchise including Dupixent (with Regeneron) for asthma and chronic rhinosinusitis with nasal polyps; a broader but overlapping competitor in allergy therapeutics.
• Teva Pharmaceutical: Supplies generic epinephrine autoinjectors competing with EpiPen in anaphylaxis and operates a broad specialty/generics portfolio with respiratory exposure.

Direct peers

• Viatris (EpiPen): Commercializes EpiPen, the dominant epinephrine autoinjector for anaphylaxis; the primary incumbent ALK's Neffy/EURneffy nasal spray is positioning to displace.
• HAL Allergy: European allergen extracts and immunotherapy manufacturer (SCIT and SLIT) operating from the Netherlands; competes head-to-head with ALK across respiratory allergens in Europe.
• Allergy Therapeutics: UK-listed specialty allergy immunotherapy company developing SCIT and SLIT products (e.g., Pollinex Quattro, Grass MATA MPL) — a direct competitor in the European allergy vaccine space.
• Stallergenes Greer: Global allergy immunotherapy competitor offering both subcutaneous and sublingual products across respiratory and food allergies; the closest like-for-like rival to ALK's SLIT tablet and SCIT portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeopen.spotify.com/show/3kIskvY6ATVleK29EjTFQu
• LinkedInlinkedin.com/company/alk-abello

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alk-Abello